Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria

Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of investigative dermatology 2015-01, Vol.135 (1), p.13-15
Hauptverfasser:	Wu, Keith C.P., Jabbar-Lopez, Zarif K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Allergic Agents - administration & dosage Antibodies, Anti-Idiotypic - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Asterias Female Histamine H1 Antagonists - administration & dosage Humans Male Omalizumab Urticaria - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
ISSN:	0022-202X 1523-1747
DOI:	10.1038/jid.2014.362